ReviewJournal of diabetes and metabolic disorders2026
Effects of chiglitazar on glycemic, lipid, and hepatic outcomes: A systematic review and meta-analysis.
Review in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Chiglitazar is a peroxisome proliferator-activated receptor pan-agonist with potential metabolic benefits. This systematic review and meta-analysis assessed its efficacy and safety versus placebo or active comparators in adults with metabolic disorders. Methods: PubMed, Scopus, and Web of Science were searched up to August 2026 for studies assessing chiglitazar in adults with metabolic disorders. Outcomes were pooled via random-effects meta-analysis with 95% confidence intervals, alongside heterogeneity, subgroup, and sensitivity analyses. Results: Five studies involving 1,457 participants were included. Chiglitazar reduced fasting glucose at 24 weeks (MD - 0.99 mmol/L, 95% CI - 1.75 to - 0.24). HbA1c decreased at 12 weeks (MD - 0.52% points, 95% CI - 0.68 to - 0.37), but its 24-week reduction was not statistically significant. Fasting insulin decreased at 12 weeks (SMD - 0.25, 95% CI - 0.39 to - 0.11), and HOMA-IR decreased at 12 and 24 weeks. Triglyceride levels decreased and HDL-C increased at both time points; total and LDL cholesterol increased at 12 weeks. At 12 weeks, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) decreased (MD - 4.44 U/L, 95% CI - 6.09 to - 2.79; and - 1.23 U/L, 95% CI - 2.28 to - 0.19, respectively). AST decreased at 24 weeks (MD - 3.03 U/L, 95% CI - 5.85 to - 0.21), whereas ALT did not significantly decrease (MD - 4.52 U/L, 95% CI - 9.34 to 0.30). No significant differences in overall or serious adverse events were detected; edema was increased (RR 8.77, 95% CI 1.60-47.97). Conclusion: Chiglitazar may improve short-term glycemic control, insulin sensitivity, selected lipid measures, and aminotransferase levels in adults with metabolic disorders. Increased edema risk, heterogeneity, and limited follow-up warrant cautious interpretation; long-term clinical benefits remain unproven. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s40200-026-02119-8.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.